Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL693886 | 0.83 | MEN1 (0.35) | BACE1MEN1KMT2AMAPK1NPC1 | |
| SCHEMBL27707573 | 0.83 | PTGS2 (0.35) | NPC1RAB9APTGS1PTGS2RPS6KA3 | |
| SCHEMBL29246765 | 0.81 | PTGS1 (0.34) | BACE1MEN1KMT2AMAPK1NPC1 | |
| SCHEMBL27707563 | 0.80 | TAAR1 (0.40) | MEN1KMT2AHPGDMAPT | |
| SCHEMBL1205890 | 0.80 | KDM4E (0.34) | MEN1KMT2AMAPK1NPC1PKM | |
| SCHEMBL618853 | 0.79 | BACE1 (0.39) | BACE1MAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL27688266 | 0.79 | AHR (0.35) | NPC1RAB9ASMN1; SMN2L3MBTL1HSD17B10 | |
| SCHEMBL27688228 | 0.79 | ALDH1A1 (0.33) | MEN1KMT2AMAPK1ALDH1A1CYP2A6 | |
| SCHEMBL27516940 | 0.79 | CYP3A4 (0.39) | MEN1KMT2AALDH1A1HSD17B10MAPT | |
| SCHEMBL9770283 | 0.78 | PTGS2 (0.41) | HPGDADORA1ADORA2APTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107205972-A | Substituted N- (2- (amino) -2-oxoethyl) benzamide inhibitors of autotaxin and their preparation and use in the treatment of LPA-dependent or LPA-mediated diseases | X-RX股份有限公司 | 2017-09-26 | — | — | CN | claimed |
| CN-102459167-B | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-04-01 | — | — | CN | claimed |
| CN-103930396-A | Aniline derivatives,their preparation and their therapeutic application | FOVEA PHARMACEUTICALS | 2014-07-16 | — | — | CN | claimed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | claimed |
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | AHMAD SALEEM (US) | 2005-06-23 | — | — | US | claimed |
| CN-1468232-A | Heterocyclic sodium/proton exchange inhibitors and method | ����˹�ж�-����˹˹������˾ | 2004-01-14 | — | — | CN | claimed |
| EP-1224183-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | claimed |
| EP-0821665-B1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LAB (US) | 2001-10-04 | — | — | EP | claimed |
| WO-2001027107-A2 | HETEROCYCLIC SODIUM/PROTON EXCHANGE INHIBITORS AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | claimed |
| US-5831115-A | CYCLOBUTANECARBOXAMIDES | ABBOTT LABORATORIES (US) | 1998-11-03 | — | — | US | claimed |
| EP-0821665-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | Abbott Laboratories (US) | 1998-02-04 | — | — | EP | claimed |
| WO-1996033159-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | claimed |
| WO-2024147306-A1 | AMIDE COMPOUND AND HARMFUL ARTHROPOD CONTROL COMPOSITION CONTAINING SAME | 住友化学株式会社 | 2024-07-11 | — | — | WO | disclosed |
| CN-107205972-A | Substituted N- (2- (amino) -2-oxoethyl) benzamide inhibitors of autotaxin and their preparation and use in the treatment of LPA-dependent or LPA-mediated diseases | X-RX股份有限公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-102459167-B | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-04-01 | — | — | CN | disclosed |
| US-7326705-B2 | Heterocyclic sodium/proton exchange inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| US-5606101-A | INTERMEDIATES FOR SQUALENE SYNTHASE INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-02-25 | — | — | US | disclosed |
| WO-1996033159-A1 | CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHASE AND PROTEIN FARNESYLTRANSFERASE | ABBOTT LABORATORIES (US) | 1996-10-24 | — | — | WO | disclosed |
| US-5488149-A | SQUALENE SYNTHASE INHIBITORS AS ANTICHOLESTEROL OR ANTILIPEMIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-01-30 | — | — | US | disclosed |
| EP-0611749-A1 | Substituted amic acid derivatives useful for treatment of arteriosclerosis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1994-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137216-A1 | Heterocyclic sodium/proton exchange inhibitors and method | NHERF1, SLC9A3, SLC9A1 | BACE1 4532/4885MEN1 3121/4885KMT2A 4440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.